

## Freedom of Information Request: Our Reference CTMUHB\_255\_22

### You asked:

Q1. In the past 3 months (latest 3 months available) how many patients have received the following treatments (for any disease):

- Berinert (Human C1-esterase inhibitor)
- Cinryze (Human C1-esterase inhibitor)
- Orladeyo (berotralstat)
- Takhzyro (Lanadelumab)
- Ruconest (Recombinant human C1-esterase inhibitor)
- Firazyr (Icatibant injection)

Q2. In the past 3 months (latest 3 months available) how many patients have received the following immunoglobulin treatments (for any disease):

- Cutaquig
- Cuvitru
- Gammanorm
- Gammaplex
- Gamunex
- Hizentra
- Hyqvia
- Intratect
- Iqymune
- Kiovig
- Privigen
- Octagam
- Panzyga
- Subgam

### Our response:

Please find provided below tables populated with the data requested. The period the data covers refers to 1<sup>st</sup> April 22 to 30<sup>th</sup> June 22, the latest 3 months available.

Where the figures are less than 5, this has been denoted by \*\*. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The

data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Q1.

<b>Medicine</b>	<b>Number of Patients</b>
Berinert (Human C1-esterase inhibitor)	0
Cinryze (Human C1-esterase inhibitor)	0
Orladeyo (berotralstat)	0
Takhzyro (Lanadelumab)	0
Ruconest (Recombinant human C1-esterase inhibitor)	0
Firazyr (Icatibant injection)	0

Q2.

<b>Medicine</b>	<b>Number of Patients</b>
Cutaquig	0
Cuvitru	0
Gammanorm	0
Gammaplex	0
Gamunex	16
Hizentra	0
Hyqvia	**
Intratect	**
Iqymune	**
Kiovig	0
Privigen	13
Octagam	**
Panzyga	0
Subgam	0